Leap Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Cypherpunk Technologies

26/03/2025 12:29

Leap Therapeutics Inc LPTX.OQ reported a quarterly adjusted loss of 37 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -46 cents.  The lone analyst forecast for the quarter was for a loss of 36 cents per share.

Reported revenue was zero​; analysts expected zero.

Leap Therapeutics Inc's reported EPS for the quarter was a loss of 37 cents​.

The company reported a quarterly loss of $15.43 million.

Leap Therapeutics Inc shares had fallen by 86.5% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 6.1% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

This summary was machine generated from LSEG data March 26 at 12:29 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.36
-0.37
Missed
Sep. 30 2024
-0.48
-0.44
Beat
Jun. 30 2024
-0.43
-0.52
Missed
Mar. 31 2024
-0.58
-0.51
Beat